Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025

Utsteder

Lytix Biopharma AS

Oslo, Norway, October 8, 2025 - Lytix Biopharma AS, a clinical-stage
immuno-oncology company, is pleased to announce that its license partner Verrica
Pharmaceuticals Inc. will present new data from its Phase II clinical trial of
VP-315 (Ruxotemitide, formerly LTX-315) for the treatment of basal cell
carcinoma (BCC) at the upcoming Society for Immunotherapy of Cancer (SITC)
Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland,
USA.

VP-315 will be featured in both an oral and a poster presentation during the
conference.
The abstract, titled "Exploratory analysis of a phase 2 multicenter study
evaluating local immune activation in the tumor microenvironment 12 weeks post
VP-315, an investigational therapy for basal cell carcinoma (BCC)", (Abstract
#529), will be presented as an oral presentation by Dr. Kenneth Tsai from the
Moffitt Cancer Center on Friday, November 7. The abstract will be available on
the SITC website on November 4, 2025.

The presentation will include exploratory analyses on local immune activation in
the tumor microenvironment following VP-315 treatment. While the primary
clinical outcomes from the Phase II study have previously been reported, this
analysis provides additional insights into immune response activation in BCC
patients.

"We are very pleased that Verrica's trial with VP-315 has been selected for oral
presentation at SITC, one of the most prominent global immuno-oncology
conferences. "This recognition underscores the potential of Lytix's technology
platform and the progress we are making in advancing our unique oncolytic
peptide approach.," said Øystein Rekdal, CEO of Lytix Biopharma.

VP-315 is licensed to Verrica Pharmaceuticals from Lytix Biopharma for certain
dermatologic oncology indications, including basal cell carcinoma and cutaneous
squamous cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell
carcinoma. Lytix retains rights to all other cancer indications.

Abstract details:
• Abstract Number: 529
• Title: Exploratory analysis of a phase 2 multicenter study evaluating local
immune activation in the tumor microenvironment 12 weeks post VP-315, an
investigational therapy for basal cell carcinoma (BCC)
• Presenting Author: Dr. Kenneth Tsai, Moffitt Cancer Center
• Presentation Type: Oral and Poster
• Presentation Day: Friday, November 7, 2025

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
[email protected]

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, Ruxotemitide
(formerly LTX-315), is a first-in-class oncolytic molecule representing a new
principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of
molecules that can work in many different cancer indications and treatment
settings, both as mono- and combination therapy. Lytix is listed on Euronext
Growth Oslo under the ticker LYTIX.

More information:
Access the news on Oslo Bors NewsWeb site

656799_Lytix Biopharma - Verrica to present at SITC 2025.pdf